TTD

ICON Public Limited Company

Fundamental data last updated:July 11, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Diagnostics & Research

Exchange

NASDAQ

County of HQ

IE

Next Earnings Date

Pending Announcement

Business Summary

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.

 


VALUATION

P/E

47.80

Market Cap ($M USD)

$10.56B

Forward P/E

9.01

PEG

0.02

PRICE TO SALES

1.28

PRICE TO BOOK

1.19

EV / EBITDA

16.36

5-Year Average P/E

Free Cash Flow Yield

12.69%

DCF Value

$213.16

Graham Number

$86.67

Price to FCF

7.87

EV to FCF

10.05

Earnings Yield

2.09%

FCF Yield

12.69%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$2.89

Next Year EPS Growth Estimate

$15.31

Next Year Revenue Growth Estimate

$864.90B

Return on Equity (ROE)

2.44%

FREE CASH FLOW

Operating Margin

12.27%

Debt-to-Equity

0.39

Piotroski F-Score

7

Altman Z-Score

1.69

Return on Invested Capital (ROIC)

7.74%

Current Ratio

1.10

Quick Ratio

1.10

Net Debt to EBITDA

3.53

Interest Coverage

5.38

Gross Profit margin

26.37%

FCF PER SHARE

$16.88

REVENUE PER SHARE

$103.83

Gainseekers Quantitative Analysis

Summary

The market seems to be significantly undervaluing ICON Public Limited Company. With a DCF value nearly double its recent trading price, the stock appears deeply discounted. The Forward P/E of 7.91 suggests robust growth expectations, yet the Altman Z-score of 1.57 raises concerns about financial stability. Despite these risks, the earnings yield of 6.22% indicates a potentially lucrative opportunity for investors seeking value. Overall, the market may be overlooking the company’s potential for growth and profitability.

AI Exposure / Tech Reliance

Operating in the Medical - Diagnostics & Research industry, ICON is well-positioned to leverage AI advancements. The sector's reliance on data analytics and diagnostics aligns with AI's strengths, offering opportunities for enhanced efficiency and innovation. This adaptability could provide a competitive edge in an evolving technological landscape.

The Bull Case

For value and GARP investors, ICON presents a compelling opportunity. The ROIC of 7.41% and a solid FCF yield of 10.48% highlight efficient capital use and cash generation. A Piotroski F-Score of 6 indicates sound financial health, while an operating margin of 12.15% showcases pricing power. These metrics suggest a company capable of delivering sustainable returns, making it an attractive buy for those seeking growth at a reasonable price.

The Bear Case

Despite its strengths, ICON faces notable challenges. The Altman Z-score of 1.57 signals potential financial distress, and the stock's distance from its 52-week high suggests technical vulnerability. Moreover, the current ratio of 1.06 barely covers short-term liabilities, indicating liquidity concerns. While the debt level is manageable, these factors could weigh heavily on future performance, warranting caution for risk-averse investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$143.50

Institutional Ownership %

1-Year Beta

1.23

Insider Buying % (6 Mo)

Distance to 52-Week High

52.94%

Distance to 52-Week Low

51.75%

EARNINGS SURPRISE %

0.91%

50-DAY SMA

$112.16

200-DAY SMA

$151.97

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.